[go: up one dir, main page]

WO2010093263A8 - Compositions et méthodes destinées au traitement et à la prévention de troubles néoplasiques - Google Patents

Compositions et méthodes destinées au traitement et à la prévention de troubles néoplasiques Download PDF

Info

Publication number
WO2010093263A8
WO2010093263A8 PCT/NZ2010/000014 NZ2010000014W WO2010093263A8 WO 2010093263 A8 WO2010093263 A8 WO 2010093263A8 NZ 2010000014 W NZ2010000014 W NZ 2010000014W WO 2010093263 A8 WO2010093263 A8 WO 2010093263A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
prevention
treatment
methods
neoplastic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NZ2010/000014
Other languages
English (en)
Other versions
WO2010093263A1 (fr
Inventor
Annette Lasham
Glen Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLIRNA BIOSCIENCES Ltd
Original Assignee
SOLIRNA BIOSCIENCES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLIRNA BIOSCIENCES Ltd filed Critical SOLIRNA BIOSCIENCES Ltd
Publication of WO2010093263A1 publication Critical patent/WO2010093263A1/fr
Publication of WO2010093263A8 publication Critical patent/WO2010093263A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions destinées au traitement et/ou à la prévention du cancer chez un mammifère, au moyen d'interférence d'ARN, ainsi que des méthodes d'utilisation de ces compositions. Lesdites compositions comprennent une molécule d'acide nucléique interférant court (siNA), qui supprime l'expression d'un gène cible impliqué dans le masquage et l'épissage de l'ARN, la translation, la transcription et la réparation de l'ADN.
PCT/NZ2010/000014 2009-02-03 2010-02-03 Compositions et méthodes destinées au traitement et à la prévention de troubles néoplasiques Ceased WO2010093263A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14958209P 2009-02-03 2009-02-03
US61/149,582 2009-02-03

Publications (2)

Publication Number Publication Date
WO2010093263A1 WO2010093263A1 (fr) 2010-08-19
WO2010093263A8 true WO2010093263A8 (fr) 2010-09-30

Family

ID=42561948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2010/000014 Ceased WO2010093263A1 (fr) 2009-02-03 2010-02-03 Compositions et méthodes destinées au traitement et à la prévention de troubles néoplasiques

Country Status (1)

Country Link
WO (1) WO2010093263A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151063A1 (en) * 1996-08-30 2002-10-17 Annette Lasham Methods for modulating apoptotic cell death
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
EP2213738B1 (fr) * 2002-11-14 2012-10-10 Dharmacon, Inc. Molécules siRNA anti Bcl-2
WO2008026946A2 (fr) * 2006-08-30 2008-03-06 Genesis Research And Development Corporation Limited Compositions et procédés destinés à traiter et à prévenir des troubles néoplastiques

Also Published As

Publication number Publication date
WO2010093263A1 (fr) 2010-08-19

Similar Documents

Publication Publication Date Title
EP2379597B8 (fr) Vecteur d'arn bicaténaire ciblant egfr pour le traitement systémique du cancer
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
WO2009129319A3 (fr) Réduction au silence de l'expression du gène csn5 au moyen d'arn interférant
WO2010056737A3 (fr) Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
WO2007095638A3 (fr) Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
WO2008150897A3 (fr) Réduction de la toxicité de l'interférence arn hors cible
WO2010051502A3 (fr) Molécules ciblant light et leurs utilisations
WO2007093050A8 (fr) Analyse de l'expression d'un gène oligonucléotidique marqué par un élément
WO2011072246A3 (fr) Modification de l'adn induite par l'effecteur tal
CL2011000730A1 (es) Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer.
BRPI1009576A2 (pt) anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente.
WO2009111676A3 (fr) Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
WO2008103761A9 (fr) Méthodes et compositions de diagnostic et de traitement du cancer basés sur la méthylation des acides nucléiques
BRPI0810418A8 (pt) membros de ligação alvo, ácido nucléico isolado, vetor de expressão, célula hospedeira, composição, métodos para produzir um membro de ligação alvo, para o tratamento ou prevenção de asma e para produzir um anticorpo contra il-25
WO2010045384A3 (fr) Arn courts en épingles à cheveux destinés à inhiber l’expression des gènes
BRPI0815392A2 (pt) Método para produzir planta transgênica, planta transgênica, uso de uma sequência de ácido nucleico exógeno, gene quimérico, vetor de transformação de planta, e , planta ou célula de planta.
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2005110067A3 (fr) Procede et compositions destines a l'interference d'arn
WO2009143371A3 (fr) Compositions comportant un arnsi des voies mtor et leurs procédés d’utilisations
HUE071824T2 (hu) Nukleinsav-konstruktumok VA RNS transzkripcióhoz
WO2010093263A8 (fr) Compositions et méthodes destinées au traitement et à la prévention de troubles néoplasiques
WO2010058393A3 (fr) Compositions et procédés pour le pronostic du cancer du côlon
WO2009143277A3 (fr) Compositions comprenant un arnsi hscn9a et leurs procédés d'utilisation
EP4077677A4 (fr) Nanoparticule d'arn pour le traitement du cancer du foie
WO2013093347A3 (fr) Procede pour le diagnostic ou le pronostic, in vitro, du cancer de l'ovaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10741459

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10741459

Country of ref document: EP

Kind code of ref document: A1